Newron Pharmaceuticals S.p.a.

Emanuela Izzo

Piero Melloni

Alessandra Restivo

Cibele Sabido-David

Elena Colombo

Simona Francisconi

Patricia Salvati

Elena Barbanti

Florian Thaler

Luca Benatti

Ruggero Fariello

Claudia Besana

Laura Faravelli

Claudia c/o Newron Pharmaceuticals SpA Besana

Florian c/o Newron Pharmaceuticals SpA Thaler

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) whereinX, Y, Z, R, R, R, R, R'R, R, R, Rhave the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) 

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.

Methods of using certain &#x3b1;-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of addictive disorders

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases.

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

&#x3b1;-Aminoamide derivatives useful in the treatment of restless legs syndrome

The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.

Growing community of inventors

Milan, Italy

Emanuela Izzo